Cargando…

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

BACKGROUND: Axitinib is an orally active and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-naïve patients with advanced/metastatic (stag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bondarenko, Igor M, Ingrosso, Antonella, Bycott, Paul, Kim, Sinil, Cebotaru, Cristina L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424571/ https://www.ncbi.nlm.nih.gov/pubmed/25929582 http://dx.doi.org/10.1186/s12885-015-1350-6

Ejemplares similares

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
por: Belani, Chandra P, et al.
Publicado: (2014)

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
por: Cohen, E. E. W., et al.
Publicado: (2014)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
por: Ioka, Tatsuya, et al.
Publicado: (2015)

Advances in doublet mechanics
por: Ferrari, Mauro, et al.
Publicado: (1997)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
por: Solomon, Benjamin, et al.
Publicado: (2022)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum‐based doublet chemotherapy and immunotherapy (SPACE study)
por: Lee, Seung Hyeun, et al.
Publicado: (2021)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
por: Yang, Kai-Lin, et al.
Publicado: (2021)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer
por: Lim, Do Hyoung, et al.
Publicado: (2010)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
por: Greystoke, Alastair, et al.
Publicado: (2017)

Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet
por: Kozłowska, Emilia, et al.
Publicado: (2020)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970)

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
por: Woll, Penella J., et al.
Publicado: (2023)

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
por: Deshpande, Hari A, et al.
Publicado: (2010)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
por: Oh, Do-Youn, et al.
Publicado: (2015)

Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis
por: Ohmoto, Akihiro, et al.
Publicado: (2022)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients
por: Liu, Di, et al.
Publicado: (2015)

Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

Advances in the design of the SuperB final doublet
por: Paoloni, E, et al.
Publicado: (2011)

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets
por: Alexa, Teodora, et al.
Publicado: (2014)

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
por: Takahashi, Toshiaki, et al.
Publicado: (2021)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy
por: van der Voort van Zyp, Noëlle, et al.
Publicado: (2022)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
por: Verschuur, Arnauld C., et al.
Publicado: (2019)

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
por: Galffy, G., et al.
Publicado: (2023)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l7mmbeobqe7ftv7p96ch76jeg0